Francisco Javier Duque
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Francisco Javier Duque has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Rafael Barrera
MINVET Research Group, Departamento de Medicina Animal, Facultad de Veterinaria, Universidad de Extremadura, 10003 Cáceres, Spain
9 shared publications - Domingo Casamian-Sorrosal
Veterinary Teaching Hospital & Department of Animal Medicine and Surgery, School of Veterinary Science Universidad Católica de Valencia San Vicente Mártir Valencia Spain
6 shared publications - Eva María Pérez Merino
Department of Animal Medicine, Hospital Clínico Veterinario, Facultad de Veterinaria, University of Extremadura, Avenida de la Universidad s/n, 10003 Cáceres, Spain
6 shared publications - José Ignacio Cristóbal Verdejo
MINVET Research Group, Departamento de Medicina Animal, Facultad de Veterinaria, Universidad de Extremadura, 10003 Cáceres, Spain
6 shared publications - Beatriz Macías-García
MINVET Group, Departamento de Medicina Animal, Facultad de Veterinaria Universidad de Extremadura Cáceres Spain
5 shared publications - Jose Maria Dominguez Roldan
Hospital Universitario Virgen del Rocío
4 shared publications
Latest Publications
- Open Access
Evaluation of the Tolerability and Efficacy of Adjuvant Treatment with Adipose Mesenchymal Stem/Stromal Cells in Dogs with Kidney Disease Secondary to Leishmaniosis
The tolerability and efficacy of treatment with allogeneic adipose-derived mesenchymal stem cells (aAMSCs) were evaluated in dogs with kidney disease secondary to canine leishmaniosis (CanL). In this non-blinded, single-center, 3-month study, twenty dogs received either conventional treatment (CT; n = 10) or conventional treatment plus an intravenous dose of aAMSCs (CT + aAMSCs; n = 10). Efficacy was assessed at days 0, 30, and 90 using plasma and urinary biomarkers. In both groups (CT, n = 6; CT + aAMSCs, n = 7), glomerular filtration rate was estimated by scintigraphy, and urinary proteomics was performed. No serious adverse events were observed, although two dogs experienced transient gastrointestinal events. No significant between-group differences occurred in renal parameters at time points. Intragroup analyses showed significant reductions in uNGAL/c in both groups and UPCR only in CT + aAMSCs. Longitudinal mixed-effects analyses revealed no significant group × time interactions for any of the evaluated variables. Urinary proteomics identified four protein entries with higher abundance in the CT + aAMSCs group at T90, although UMAP showed no separation between groups. A single intravenous aAMSCs dose was well tolerated but provided no renal benefits over conventional treatment. Further studies should evaluate alternative dosing protocols.
Open AccessEvaluation of the Tolerability and Efficacy of Adjuvant Treatment with Adipose Mesenchymal Stem/Stromal Cells in Dogs with Kidney Disease Secondary to Leishmaniosis
The tolerability and efficacy of treatment with allogeneic adipose-derived mesenchymal stem cells (aAMSCs) were evaluated in dogs with kidney disease secondary to canine leishmaniosis (CanL). In this non-blinded, single-center, 3-month study, twenty dogs received either conventional treatment (CT; n = 10) or conventional treatment plus an intravenous dose of aAMSCs (CT + aAMSCs; n = 10). Efficacy was assessed at days 0, 30, and 90 using plasma and urinary biomarkers. In both groups (CT, n = 6; CT + aAMSCs, n = 7), glomerular filtration rate was estimated by scintigraphy, and urinary proteomics was performed. No serious adverse events were observed, although two dogs experienced transient gastrointestinal events. No significant between-group differences occurred in renal parameters at time points. Intragroup analyses showed significant reductions in uNGAL/c in both groups and UPCR only in CT + aAMSCs. Longitudinal mixed-effects analyses revealed no significant group × time interactions for any of the evaluated variables. Urinary proteomics identified four protein entries with higher abundance in the CT + aAMSCs group at T90, although UMAP showed no separation between groups. A single intravenous aAMSCs dose was well tolerated but provided no renal benefits over conventional treatment. Further studies should evaluate alternative dosing protocols.
- Open Access
- 24 July 2026
- Published by MDPI AG in Veterinary Sciences
- Vol. 13 (8) , 735
Exploratory Evaluation of Cardiac Fatty Acid-Binding Protein (H-FABP), Troponin I, NT-proBNP, Echocardiography, and Holter Monitoring for the Assessment of Doxorubicin-Induced Cardiac Damage in Dogs
Doxorubicin-induced cardiotoxicity is an important concern in veterinary oncology, and early detection of myocardial injury remains clinically challenging. This exploratory pilot study described changes in cardiac fatty acid-binding protein (h-FABP), cardiac troponin I (cTnI), NT-proBNP, conventional echocardiographic variables, and 24-h Holter-derived heart rate variability parameters in dogs with hemangiosarcoma treated with doxorubicin. Fourteen dogs were prospectively evaluated before treatment initiation and one week after the third doxorubicin dose, corresponding to a cumulative dose of 90 mg/m2. The study did not include a control group, a predefined cardiotoxicity endpoint, or diagnostic-performance analysis. Plasma biomarkers, echocardiographic parameters, ventricular arrhythmic events, and Holter-derived time- and frequency-domain heart rate variability variables were compared between both time points. Cardiac troponin I increased significantly after three doxorubicin doses, from a median of 0.05 ng/mL to 0.15 ng/mL (p = 0.002). In contrast, h-FABP did not change significantly, with median values of 2.43 ng/mL at baseline and 2.62 ng/mL after treatment (p = 0.27). NT-proBNP also showed no significant change (p = 0.87). Among echocardiographic variables, E-point septal separation, fractional shortening, ejection fraction, LA/Ao, and LVDd index did not change significantly. Ventricular arrhythmic events were infrequent and were described descriptively, whereas Holter-derived HRV variables did not show statistically significant differences between time points. In this exploratory cohort, cTnI increased after three doxorubicin doses, whereas h-FABP and NT-proBNP did not change significantly at the evaluated time point. Because h-FABP was measured one week after treatment, its potential short-term post-infusion release cannot be assessed. Larger studies with serial early sampling, predefined cardiotoxicity endpoints, appropriate control groups, and adjusted statistical analyses are required.
- 24 July 2026
- Published by MDPI AG in Veterinary Sciences
- Vol. 13 (8) , 735
Open AccessExploratory Evaluation of Cardiac Fatty Acid-Binding Protein (H-FABP), Troponin I, NT-proBNP, Echocardiography, and Holter Monitoring for the Assessment of Doxorubicin-Induced Cardiac Damage in Dogs
Doxorubicin-induced cardiotoxicity is an important concern in veterinary oncology, and early detection of myocardial injury remains clinically challenging. This exploratory pilot study described changes in cardiac fatty acid-binding protein (h-FABP), cardiac troponin I (cTnI), NT-proBNP, conventional echocardiographic variables, and 24-h Holter-derived heart rate variability parameters in dogs with hemangiosarcoma treated with doxorubicin. Fourteen dogs were prospectively evaluated before treatment initiation and one week after the third doxorubicin dose, corresponding to a cumulative dose of 90 mg/m2. The study did not include a control group, a predefined cardiotoxicity endpoint, or diagnostic-performance analysis. Plasma biomarkers, echocardiographic parameters, ventricular arrhythmic events, and Holter-derived time- and frequency-domain heart rate variability variables were compared between both time points. Cardiac troponin I increased significantly after three doxorubicin doses, from a median of 0.05 ng/mL to 0.15 ng/mL (p = 0.002). In contrast, h-FABP did not change significantly, with median values of 2.43 ng/mL at baseline and 2.62 ng/mL after treatment (p = 0.27). NT-proBNP also showed no significant change (p = 0.87). Among echocardiographic variables, E-point septal separation, fractional shortening, ejection fraction, LA/Ao, and LVDd index did not change significantly. Ventricular arrhythmic events were infrequent and were described descriptively, whereas Holter-derived HRV variables did not show statistically significant differences between time points. In this exploratory cohort, cTnI increased after three doxorubicin doses, whereas h-FABP and NT-proBNP did not change significantly at the evaluated time point. Because h-FABP was measured one week after treatment, its potential short-term post-infusion release cannot be assessed. Larger studies with serial early sampling, predefined cardiotoxicity endpoints, appropriate control groups, and adjusted statistical analyses are required.
- Open Access
- 18 June 2026
- Published by Elsevier in The Veterinary Journal
- Vol. 318, 106751
Vascular ultrasonographic findings in canine and feline patients with leishmaniosis
- 18 June 2026
- Published by Elsevier in The Veterinary Journal
- Vol. 318, 106751
Open AccessVascular ultrasonographic findings in canine and feline patients with leishmaniosis
- Open Access
- 3 March 2026
- Published by MDPI AG in Veterinary Sciences
- Vol. 13 (3) , 243
Evaluation of Urinary Tubular Biomarkers in Dogs with Myxomatous Mitral Valve Disease Across ACVIM Stages
Myxomatous mitral valve disease (MMVD) is the most common acquired heart valve disease in dogs and it may contribute to cardiovascular–renal axis disorders (CvRD) in dogs. Sensitive and early biomarkers of renal involvement are needed. In this prospective and observational study, 84 dogs were enrolled (20 healthy dogs and 64 dogs with MMVD), categorised using the American College of Veterinary Internal Medicine guidelines. Serum and urinary parameters were analysed, including tubular biomarkers expressed as creatinine-ratios: urinary alkaline phosphatase (uALPc), gamma-glutamyl transferase (uGGTc), N-acetyl-β-D-glucosaminidase (uNAGc), and cystatin C (uCystc). uALPc, uGGTc, and uNAGc were higher in MMVD than in controls; uALPc and uGGTc were increased from stage B1, uNAGc was higher in stages with cardiomegaly (B2 and C+D), and uCystc increased mainly in clinical stages (C+D). Serum renal markers increased only in clinical stages. ROC analysis showed good discrimination for MMVD with uALPc (AUC 0.87) and uGGTc (0.86); for cardiomegaly with uALPc (0.77) and uNAGc (0.75); and for congestive heart failure with SDMA (0.85) and uCystc (0.75). No urinary biomarker was associated with daily furosemide dose. Urinary tubular biomarkers, particularly uALPc and uGGTc, detect early CvRD in dogs with MMVD and complement traditional serum markers.
- 3 March 2026
- Published by MDPI AG in Veterinary Sciences
- Vol. 13 (3) , 243
Open AccessEvaluation of Urinary Tubular Biomarkers in Dogs with Myxomatous Mitral Valve Disease Across ACVIM Stages
Myxomatous mitral valve disease (MMVD) is the most common acquired heart valve disease in dogs and it may contribute to cardiovascular–renal axis disorders (CvRD) in dogs. Sensitive and early biomarkers of renal involvement are needed. In this prospective and observational study, 84 dogs were enrolled (20 healthy dogs and 64 dogs with MMVD), categorised using the American College of Veterinary Internal Medicine guidelines. Serum and urinary parameters were analysed, including tubular biomarkers expressed as creatinine-ratios: urinary alkaline phosphatase (uALPc), gamma-glutamyl transferase (uGGTc), N-acetyl-β-D-glucosaminidase (uNAGc), and cystatin C (uCystc). uALPc, uGGTc, and uNAGc were higher in MMVD than in controls; uALPc and uGGTc were increased from stage B1, uNAGc was higher in stages with cardiomegaly (B2 and C+D), and uCystc increased mainly in clinical stages (C+D). Serum renal markers increased only in clinical stages. ROC analysis showed good discrimination for MMVD with uALPc (AUC 0.87) and uGGTc (0.86); for cardiomegaly with uALPc (0.77) and uNAGc (0.75); and for congestive heart failure with SDMA (0.85) and uCystc (0.75). No urinary biomarker was associated with daily furosemide dose. Urinary tubular biomarkers, particularly uALPc and uGGTc, detect early CvRD in dogs with MMVD and complement traditional serum markers.
- Open Access
- 28 January 2026
- Published by MDPI AG in Preprints.org
Urinary Tubular Biomarkers in Canine Myxomatous Mitral Valve Disease: Early Indicators of Alterations in the Cardiovascular-Renal Axis
Myxomatous mitral valve disease (MMVD) is the most common acquired heart valve disease in dogs and it may contribute to cardiovascular-renal axis disorders (CvRD) in dogs. Sensitive and early biomarkers of renal involvement are needed. In this prospective and observational study, 84 dogs were enrolled (20 healthy dogs and 64 dogs with MMVD, categorized using the American College of Veterinary Internal Medicine guidelines. Serum and urinary parameters were analyzed, including tubular biomarkers expressed as creatinine-ratios: urinary alkaline phosphatase (uALPc), gamma-glutamyl transferase (uGGTc), N-acetyl-β-D-glucosaminidase (uNAGc) and cystatin C (uCystc). uALPc, uGGTc and uNAGc were higher in MMVD than in controls; uALPc and uGGTc were increased from stage B1, uNAGc was higher in stages with cardiomegaly (B2 and C+D), and uCystc increased mainly in clinical stages (C+D). Serum renal markers increased only in clinical stages. ROC analysis showed good discrimination for MMVD with uALPc (AUC 0.87) and uGGTc (0.86); for cardiomegaly with uALPc (0.77) and uNAGc (0.75); and for congestive heart failure with SDMA (0.85) and uCystc (0.75). No urinary biomarker was associated with daily furosemide dose. Urinary tubular biomarkers, particularly uALPc and uGGTc, detect early CvRD in dogs with MMVD and complement traditional serum markers.
- 28 January 2026
- Published by MDPI AG in Preprints.org
Open AccessUrinary Tubular Biomarkers in Canine Myxomatous Mitral Valve Disease: Early Indicators of Alterations in the Cardiovascular-Renal Axis
Myxomatous mitral valve disease (MMVD) is the most common acquired heart valve disease in dogs and it may contribute to cardiovascular-renal axis disorders (CvRD) in dogs. Sensitive and early biomarkers of renal involvement are needed. In this prospective and observational study, 84 dogs were enrolled (20 healthy dogs and 64 dogs with MMVD, categorized using the American College of Veterinary Internal Medicine guidelines. Serum and urinary parameters were analyzed, including tubular biomarkers expressed as creatinine-ratios: urinary alkaline phosphatase (uALPc), gamma-glutamyl transferase (uGGTc), N-acetyl-β-D-glucosaminidase (uNAGc) and cystatin C (uCystc). uALPc, uGGTc and uNAGc were higher in MMVD than in controls; uALPc and uGGTc were increased from stage B1, uNAGc was higher in stages with cardiomegaly (B2 and C+D), and uCystc increased mainly in clinical stages (C+D). Serum renal markers increased only in clinical stages. ROC analysis showed good discrimination for MMVD with uALPc (AUC 0.87) and uGGTc (0.86); for cardiomegaly with uALPc (0.77) and uNAGc (0.75); and for congestive heart failure with SDMA (0.85) and uCystc (0.75). No urinary biomarker was associated with daily furosemide dose. Urinary tubular biomarkers, particularly uALPc and uGGTc, detect early CvRD in dogs with MMVD and complement traditional serum markers.
- Open Access
- 28 November 2023
- Published by Springer Nature in Veterinary Research Communications
- Vol. 48 (2) , 901-910
Oxidative stress in dogs with chronic inflammatory enteropathy treated with allogeneic mesenchymal stem cells
The search for new biomarkers in patients with chronic inflammatory enteropathy (CIE) is ongoing in the human and veterinary medicine fields. Oxidative stress biomarkers (malondialdehyde [MDA], reduced glutathione [GSH], and albumin) have been studied in humans with chronic enteropathies, but among them, only albumin has been studied in dogs with CIE. Moreover, the effect of mesenchymal stem cell (MSCs) treatment with or without prednisone on these parameters has never been studied in dogs with CIE. These parameters were compared between healthy dogs (n = 12) and dogs with CIE, and before and 1, 3, 6, and 12 months after the treatment with MSCs alone (n = 9) or together with prednisone (n = 11). The relationship between the Canine Inflammatory Bowel Disease Activity Index (CIBDAI) and oxidative stress was evaluated. Albumin was the only parameter that significantly differed between dogs with CIE and healthy dogs (p = 0,037). Differences were observed only in albumin values after combined treatment with MSCs and prednisone. No differences were observed in MDA and GSH after treatment with MSCs with or without prednisone. Albumin could help stage canine CIE, as well as its prognosis, as has already been demonstrated, although it is essential to evaluate this parameter for its antioxidant capacity, and therefore it could be a good biomarker of oxidative stress in this pathology. However, the treatment with MSCs seems unable to modify any of the analyzed oxidative stress parameters.
- 28 November 2023
- Published by Springer Nature in Veterinary Research Communications
- Vol. 48 (2) , 901-910
Open AccessOxidative stress in dogs with chronic inflammatory enteropathy treated with allogeneic mesenchymal stem cells
The search for new biomarkers in patients with chronic inflammatory enteropathy (CIE) is ongoing in the human and veterinary medicine fields. Oxidative stress biomarkers (malondialdehyde [MDA], reduced glutathione [GSH], and albumin) have been studied in humans with chronic enteropathies, but among them, only albumin has been studied in dogs with CIE. Moreover, the effect of mesenchymal stem cell (MSCs) treatment with or without prednisone on these parameters has never been studied in dogs with CIE. These parameters were compared between healthy dogs (n = 12) and dogs with CIE, and before and 1, 3, 6, and 12 months after the treatment with MSCs alone (n = 9) or together with prednisone (n = 11). The relationship between the Canine Inflammatory Bowel Disease Activity Index (CIBDAI) and oxidative stress was evaluated. Albumin was the only parameter that significantly differed between dogs with CIE and healthy dogs (p = 0,037). Differences were observed only in albumin values after combined treatment with MSCs and prednisone. No differences were observed in MDA and GSH after treatment with MSCs with or without prednisone. Albumin could help stage canine CIE, as well as its prognosis, as has already been demonstrated, although it is essential to evaluate this parameter for its antioxidant capacity, and therefore it could be a good biomarker of oxidative stress in this pathology. However, the treatment with MSCs seems unable to modify any of the analyzed oxidative stress parameters.
- 8 February 2023
- Published by Wiley in Veterinary Record
- Vol. 192 (10) , e2683
Evaluation of heart fatty acid‐binding protein as a biomarker for canine leishmaniosis
Background: Myocarditis frequently occurs in canine leishmaniosis (CanL). Heart fatty acid‐binding protein (HFABP) is a biomarker of myocardial damage. Methods: This study aimed to compare HFABP concentration (HFABPc) in healthy dogs and dogs at different stages of CanL and evaluate the correlation of this biomarker with several clinicopathological and echocardiographic variables. Thirty‐one dogs diagnosed with CanL and 10 healthy dogs were included. Results: HFABPc was not statistically different ( p > 0.05) between groups of dogs at different LeishVet stages of CanL or between groups with high versus low to intermediate serology titres. In 70% of CanL dogs, HFABPc was within the 95% confidence interval limits of the mean of healthy dogs. A moderate negative correlation with globulin ( r = −0.519; p = 0.03) and haematocrit (HCT) ( r = −0.538; p = 0.02) was observed. No other significant correlation ( p > 0.05) was observed with any other variable. Limitations: Many statistical tests were performed, and therefore, type I error cannot be ruled out. Conclusion: HFABPc is not consistently elevated in dogs with CanL and is not associated with the severity of the disease, or most echocardiographic or clinicopathological variables studied. The correlation with globulin and HCT was not strong and not considered clinically significant. HFABPc lacks sufficient predictive capacity in dogs with CanL, discouraging further research or clinical use of this biomarker in this disease.
- 8 February 2023
- Published by Wiley in Veterinary Record
- Vol. 192 (10) , e2683
Evaluation of heart fatty acid‐binding protein as a biomarker for canine leishmaniosis
Background: Myocarditis frequently occurs in canine leishmaniosis (CanL). Heart fatty acid‐binding protein (HFABP) is a biomarker of myocardial damage. Methods: This study aimed to compare HFABP concentration (HFABPc) in healthy dogs and dogs at different stages of CanL and evaluate the correlation of this biomarker with several clinicopathological and echocardiographic variables. Thirty‐one dogs diagnosed with CanL and 10 healthy dogs were included. Results: HFABPc was not statistically different ( p > 0.05) between groups of dogs at different LeishVet stages of CanL or between groups with high versus low to intermediate serology titres. In 70% of CanL dogs, HFABPc was within the 95% confidence interval limits of the mean of healthy dogs. A moderate negative correlation with globulin ( r = −0.519; p = 0.03) and haematocrit (HCT) ( r = −0.538; p = 0.02) was observed. No other significant correlation ( p > 0.05) was observed with any other variable. Limitations: Many statistical tests were performed, and therefore, type I error cannot be ruled out. Conclusion: HFABPc is not consistently elevated in dogs with CanL and is not associated with the severity of the disease, or most echocardiographic or clinicopathological variables studied. The correlation with globulin and HCT was not strong and not considered clinically significant. HFABPc lacks sufficient predictive capacity in dogs with CanL, discouraging further research or clinical use of this biomarker in this disease.
- Open Access
Complete Blood Count-Derived Inflammatory Markers Changes in Dogs with Chronic Inflammatory Enteropathy Treated with Adipose-Derived Mesenchymal Stem Cells
Adipose-derived mesenchymal stem cells (Ad-MSCs) exhibit anti-inflammatory and immunomodulatory activities. The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) have been reported as novel biomarkers of the inflammatory state; however, they have never been examined in dogs with chronic inflammatory enteropathy (CIE) treated with Ad-MSCs. This study aimed to compare the clinical evolution and the changes in the NLR, PLR, and SII in dogs with CIE before and after cell therapy. Sixteen dogs with CIE were administered a single intravenous dose of Ad-MSCs. The canine chronic enteropathy clinical activity index (CCECAI), NLR, PLR, and SII were assessed before treatment (T0) and at 2 (T2) and 9 (T9) months post-treatment and compared over time and with the reference values obtained from a group of healthy dogs. NLR, PLR, and SII were significantly increased at T0 compared to the reference values, decreasing significantly over time. At T9, the NLR and SII did not differ from the reference values, but PLR remained above the reference values. A correlation was observed between CCECAI and the three markers. These findings show that the clinical improvement of dogs with CIE treated with Ad-MSCs is accompanied by a normalization of the inflammatory status.
Open AccessComplete Blood Count-Derived Inflammatory Markers Changes in Dogs with Chronic Inflammatory Enteropathy Treated with Adipose-Derived Mesenchymal Stem Cells
Adipose-derived mesenchymal stem cells (Ad-MSCs) exhibit anti-inflammatory and immunomodulatory activities. The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) have been reported as novel biomarkers of the inflammatory state; however, they have never been examined in dogs with chronic inflammatory enteropathy (CIE) treated with Ad-MSCs. This study aimed to compare the clinical evolution and the changes in the NLR, PLR, and SII in dogs with CIE before and after cell therapy. Sixteen dogs with CIE were administered a single intravenous dose of Ad-MSCs. The canine chronic enteropathy clinical activity index (CCECAI), NLR, PLR, and SII were assessed before treatment (T0) and at 2 (T2) and 9 (T9) months post-treatment and compared over time and with the reference values obtained from a group of healthy dogs. NLR, PLR, and SII were significantly increased at T0 compared to the reference values, decreasing significantly over time. At T9, the NLR and SII did not differ from the reference values, but PLR remained above the reference values. A correlation was observed between CCECAI and the three markers. These findings show that the clinical improvement of dogs with CIE treated with Ad-MSCs is accompanied by a normalization of the inflammatory status.
- Open Access
- 1 May 2022
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 36 (3) , 957-965
Relationship between serum cobalamin concentration and endoscopic ileal appearance and histology in dogs with chronic inflammatory enteropathy
Background: It has not been determined whether ileal appearance differs among dogs with chronic inflammatory enteropathy (CIE) and different serum concentrations of cobalamin. Objective: To compare endoscopic and histologic ileal findings in dogs with CIE and different serum cobalamin concentrations and then evaluate the correlation of ileal changes to cobalamin serum concentration using updated scoring systems to assess the ileum. Animals: Sixty-eight dogs with CIE. Methods: Retrospective study. Frequency of ileal features and ileal histologic and endoscopic scores (IHS and IES) were obtained and compared among CIE dogs with severe hypocobalaminemia (SHC; 350 ng/L). The correlation of IHS and IES with cobalamin was evaluated. Results: Friability, villus atrophy, crypt dilatation, epithelial injury, and intraepithelial lymphocytes were more frequent in SHC than in NC dogs (all P ≤ .01). Median SHC-IES (2; range, 0-4) was higher than NC-IES (1; range, 0-5; P = .004). Median SHC-IHS (6; range, 3-9) was higher than HC-IHS (4; range, 1-7; P < .001) and NC-IHS (3; range, 1-8; P < .001). Cobalamin concentration correlated negatively with IES (ρ = −.34, P = .005) and IHS (ρ = −.58, P < .001). Conclusions and Clinical Importance: Ileal features and involvement degree markedly differed when cobalamin was 350 ng/L in CIE dogs. With updated scales to assess the mucosa, greater ileal damage was associated with lower serum cobalamin concentration.
- 1 May 2022
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 36 (3) , 957-965
Open AccessRelationship between serum cobalamin concentration and endoscopic ileal appearance and histology in dogs with chronic inflammatory enteropathy
Background: It has not been determined whether ileal appearance differs among dogs with chronic inflammatory enteropathy (CIE) and different serum concentrations of cobalamin. Objective: To compare endoscopic and histologic ileal findings in dogs with CIE and different serum cobalamin concentrations and then evaluate the correlation of ileal changes to cobalamin serum concentration using updated scoring systems to assess the ileum. Animals: Sixty-eight dogs with CIE. Methods: Retrospective study. Frequency of ileal features and ileal histologic and endoscopic scores (IHS and IES) were obtained and compared among CIE dogs with severe hypocobalaminemia (SHC; 350 ng/L). The correlation of IHS and IES with cobalamin was evaluated. Results: Friability, villus atrophy, crypt dilatation, epithelial injury, and intraepithelial lymphocytes were more frequent in SHC than in NC dogs (all P ≤ .01). Median SHC-IES (2; range, 0-4) was higher than NC-IES (1; range, 0-5; P = .004). Median SHC-IHS (6; range, 3-9) was higher than HC-IHS (4; range, 1-7; P < .001) and NC-IHS (3; range, 1-8; P < .001). Cobalamin concentration correlated negatively with IES (ρ = −.34, P = .005) and IHS (ρ = −.58, P < .001). Conclusions and Clinical Importance: Ileal features and involvement degree markedly differed when cobalamin was 350 ng/L in CIE dogs. With updated scales to assess the mucosa, greater ileal damage was associated with lower serum cobalamin concentration.
- Open Access
Effects of Allogeneic Mesenchymal Stem Cell Transplantation in Dogs with Inflammatory Bowel Disease Treated with and without Corticosteroids
Mesenchymal stem cells have proven to be a promising alternative to conventional steroids to treat canine inflammatory bowel disease (IBD). However, their administration requires a washout period of immunosuppressive drugs that can lead to an exacerbation of the symptoms. Therefore, the feasibility and effects of the combined application of stem cells and prednisone in IBD-dogs without adequate response to corticosteroids was evaluated for the first time in this study over a long- term follow up. Two groups of dogs with IBD, one without treatment and another with prednisone treatment, received a single infusion of stem cells. The clinical indices, albumin and cobalamin were determined prior to the infusion and after one, three, six and 12 months. In both groups, all parameters significantly improved at each time point. In parallel, the steroid dosage was gradually reduced until it was suppressed in all patients a year after the cell therapy. Therefore, cell therapy can significantly and safely improve the disease condition in dogs with IBD receiving or not receiving prednisone. Furthermore, the steroid dosage can be significantly reduced or cancelled after the stem cell infusion. Their beneficial effects are stable over time and are long lasting.
Open AccessEffects of Allogeneic Mesenchymal Stem Cell Transplantation in Dogs with Inflammatory Bowel Disease Treated with and without Corticosteroids
Mesenchymal stem cells have proven to be a promising alternative to conventional steroids to treat canine inflammatory bowel disease (IBD). However, their administration requires a washout period of immunosuppressive drugs that can lead to an exacerbation of the symptoms. Therefore, the feasibility and effects of the combined application of stem cells and prednisone in IBD-dogs without adequate response to corticosteroids was evaluated for the first time in this study over a long- term follow up. Two groups of dogs with IBD, one without treatment and another with prednisone treatment, received a single infusion of stem cells. The clinical indices, albumin and cobalamin were determined prior to the infusion and after one, three, six and 12 months. In both groups, all parameters significantly improved at each time point. In parallel, the steroid dosage was gradually reduced until it was suppressed in all patients a year after the cell therapy. Therefore, cell therapy can significantly and safely improve the disease condition in dogs with IBD receiving or not receiving prednisone. Furthermore, the steroid dosage can be significantly reduced or cancelled after the stem cell infusion. Their beneficial effects are stable over time and are long lasting.